Published Online: Thursday, March 1, 2007

Drugmakers are not keeping their promises. They have yet to start more than 2 of every 3 pending studies they said they would conduct after their products received FDA approval.

According to data posted on the agency's Web site, 899 of 1259 postapproval studies had not started as of September 30, 2006. The figures do not reflect completed studies.

To receive FDA approval, drugmakers oftentimes agree to perform additional studies of safety, dosing, and other issues after medications enter the marketplace. The studies are usually voluntary, and the agency cannot enforce fines for failing to conduct them.

Consumer groups and some lawmakers are urging legislation to give the FDA more authority over the studies.

The newly released FDA statistics indicated that 184 studies were on or ahead of schedule, and 144 had been submitted for agency review or terminated. Some of the studies—about 31—were labeled "delayed."

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues